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Central nervous system (CNS) relapse after allogeneic hematopoietic stem cell transplantation (HSCT) confers
a poor prognosis in adult patients with acute lymphoblastic leukemia (ALL). Preventing CNS relapse after
HSCT remains a therapeutic challenge, and criteria for post-HSCT CNS prophylaxis have not been addressed.
In a 3-center retrospective analysis, we reviewed the data for 457 adult patients with ALL who received a ﬁrst
allogeneic HSCT in ﬁrst or second complete remission (CR). All patients received CNS prophylaxis as part of
their upfront therapy for ALL, but post-transplantation CNS prophylaxis practice varied by institution and was
administered to 48% of the patients. Eighteen patients (4%) developed CNS relapse after HSCT (isolated CNS
relapse, n ¼ 8; combined bone marrow and CNS relapse, n ¼ 10). Patients with a previous history of CNS
involvement with leukemia had a signiﬁcantly higher rate for CNS relapse (P ¼ .002), and pretransplantation
CNS involvement was the only risk factor for post-transplantation CNS relapse found in this study. We failed
to ﬁnd a signiﬁcant effect of post-transplantation CNS prophylaxis to prevent relapse after transplantation.
Furthermore, no beneﬁt for post-transplantation CNS prophylaxis could be detected when a subgroup
analysis of patients with (P ¼ .10) and without previous CNS involvement (P ¼ .52) was performed. Finally, we
could not ﬁnd any signiﬁcant effect for intensity of the transplantation conditioning regimen on CNS relapse
after HSCT. In conclusion, CNS relapse is an uncommon event after HSCT for patients with ALL in CR1 or CR2,
but with higher risk among patients with CNS involvement before transplantation. Furthermore, neither the
use of post-HSCT CNS prophylaxis nor the intensity of the HSCT conditioning regimen made a signiﬁcant
difference in the rate of post-HSCT CNS relapse.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) is an effective treatment for acute lymphoblastic
leukemia (ALL), resulting in long-term remission [1]. Despite
advances in therapy, disease progression remains the major
cause of mortality after allogeneic HSCT, accounting for 20%
to 50% of all deaths [2-4]. The central nervous system (CNS) isdgments on page 1771.
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14.07.005the most common extramedullary site of disease progression
after transplantation in ALL [4].
Although the use of CNS prophylaxis as part of the upfront
treatment for ALL has led to signiﬁcant decreases in CNS
relapse and improved outcomes overall [5,6], the routine use
of post-HSCT prophylactic CNS therapy as a strategy to pre-
vent CNS relapse after transplantation is still controversial.
Studies that utilized post-HSCT CNS prophylaxis have re-
ported disparate results and there is no generalized
consensus regarding the role of post-transplantation CNS
prophylaxis to prevent CNS relapse [7-10]. Furthermore, the
increasing use of reduced-intensity transplantation condi-
tioning therapies with possibly decreased CNS penetration
makes it evenmore imperative that we try to understand the
beneﬁt, if any, of post-HSCT CNS prophylaxis.Transplantation.
Table 1
Patient and Transplantation Characteristics
Characteristic No Post-HSCT
CNS
Prophylaxis
(n ¼ 238)
Received
Post-HSCT
CNS
Prophylaxis
(n ¼ 219)
P Value
Center < .0001
MDACC 193 45
FHCRC 38 161
RMC 7 13
Age at HSCT,
median (range), yr
38 (18-70) 38 (19-76) .78
Sex .34
Female 92 95
Male 146 124
Lineage 1.00
B cell 201 188
T cell 33 30
Unknown 4 1
Cytogenetic risk group .65
Good 13 8
Intermediate 86 87
Poor 110 102
Unknown 29 22
Status at HSCT .002
CR1 126 147
CR2 112 72
Pre-HSCT CNS disease .06
None 209 174
At diagnosis 15 23
At ﬁrst relapse 11 18
Missing 3 4
Preparative regimen .89
Myeloablative 204 189
Nonmyeloablative or RIC 34 30
Allotype .95
HLA matched-related 98 91
HLA matched unrelated 86 80
HLA mismatched-related 9 10
HLA mismatched unrelated 45 38
Graft source .001
Bone marrow 65 48
Peripheral blood 136 157
Cord blood 37 14
Relapse .08
Total 60 74
CNS 6 12
Graft-versus-host disease
Acute, grades II-IV 100 156
Chronic, limited,
and/or extensive
55 125
RIC indicates reduced-intensity conditioning.
A. Hamdi et al. / Biol Blood Marrow Transplant 20 (2014) 1767e17711768The practice of post-HSCT prophylactic CNS therapy var-
ies from center to center. To determine the role of post-HSCT
prophylactic CNS therapy in preventing CNS relapse in ALL
patients, we designed a study in centers with different post-
HSCT CNS therapy practice and reviewed the data of 457
patients with ALL who received ﬁrst allogeneic HSCT in ﬁrst
or second complete remission (CR).
PATIENTS AND METHODS
Population
In this multicenter retrospective study, we studied all adult (age 18
years) ALL patients who underwent a ﬁrst allogeneic HSCT at MD Anderson
Cancer Center (MDACC), Fred Hutchinson Cancer Research Center (FHCRC),
or Rabin Medical Center (RMC) in Israel between 2000 and 2011. We
included all adult ALL patients who underwent transplantation in ﬁrst or
second CR. Before the transplantation procedure, all patients received
intrathecal methotrexate (MTX), and/or cytarabine, and/or craniospinal
irradiation as part of their standard induction and consolidation treatment.
Post-transplantation CNS Prophylaxis
The practice of CNS disease prophylaxis varied between MDACC, FHCRC,
and RMC. At MDACC, generally only patients with a previous history of CNS
disease were offered post-transplantation CNS prophylaxis with intrathecal
cytarabine, alternating with MTX, for 6 to 8 monthly infusions as tolerated;
alternatively, they could receive craniospinal radiation therapy (dose 24 Gy
in 12 daily fractions) or boost (12 Gy in 6 daily fractions) to the CNS as part of
their scheduled total body irradiation (12 Gy in 4 daily fractions) at the time
of transplantation conditioning. At FHCRC, all patients with and without
history of CNS involvement before transplantation were routinely admin-
istered post-transplantation CNS prophylaxis, most commonly with intra-
thecal or intraventricular MTX for 4 to 6 doses every 2 weeks, as tolerated.
Patients with CNS involvement incidentally found during the pre-
transplantation evaluation that failed to clear with 1 to 2 doses of MTX
received cranial-spinal irradiation immediately before or during condi-
tioning. Similarly, at RMC, all patients, regardless of previous CNS disease,
were given 4 injections of intrathecal MTX, with the ﬁrst dose usually
administered 1 month after transplantation. Ongoing transplantation tox-
icities and/or thrombocytopenia may be among the reasons for patients at
FHCRC or RMC to not receive post-HSCT CNS prophylaxis.
Deﬁnitions
Relapse into the CNS was deﬁned as unequivocal morphologic evidence
of leukemic blasts in the cerebrospinal ﬂuid or cranial nerve palsies, or a
nonhemorrhagic mass seen in cranial computed tomography or magnetic
resonance imaging because of inﬁltration by leukemia cells. Cytogenetic
abnormalities were classiﬁed based on previously published reports [11].
The intensity of the conditioning regimens were deﬁned according to
the Center for International Blood and Marrow Transplantation Research
criteria [12].
Statistics
We assessed the cumulative incidence of systemic and CNS relapses in a
competing risks framework with a competing risk of nonrelapse death.
Because data from second and subsequent relapses were not available,
patients whose ﬁrst relapse did not include CNS involvement were censored
at the time of relapse. To analyze the association between post-HSCT CNS
prophylactic therapy (which was givenwithin the ﬁrst 3 months after HSCT)
and CNS relapse, we used a landmark cumulative incidence analysis,
including only patients who had not relapsed or died by 3 months after
HSCT; landmark analysis was not used for total relapse or survival analyses.
The Fisher exact test and the Wilcoxon rank-sum test were used to compare
categorical and continuous variables between patients with CNS prophy-
laxis and those without.
RESULTS
Patient and Transplantation Characteristics
We included 457 adult patients with ALL with a median
age 38 years (range, 18 to 76 years). Characteristics of pa-
tients are presented in Table 1. Two hundred and seventy-
three patients underwent transplantation in ﬁrst CR and
184 in second CR. Sixty-seven patients (15%) had a history of
pre-HSCT CNS involvement either at diagnosis (n ¼ 38) or
after ﬁrst relapse (n ¼ 29). The median follow-up for the 213
surviving patients was 3.0 years. Because of differing practicepatterns, only 19% of patients at MDACC received post-
transplantation CNS prophylaxis, in contrast to 79% of
patients from FHCRC and RMC (P < .0001). Overall, 217 pa-
tients (47%) received post-transplantation intrathecal CNS
prophylaxis with intrathecal MTX, cytarabine, or both agents
for a median of 4 treatment cycles (range, 1 to 10). Two
patients received prophylactic CNS radiotherapy after
transplantation.CNS Relapse after Transplantation
The incidence of CNS relapse after transplantation in the
entire cohort was 4%, with an incidence of 13% in patients
with history of CNS involvement before transplantation.
Characteristics of the 18 patients who developed CNS relapse
after transplantation are described in Table 2. Among the 18
relapses, 8 were isolated CNS relapse and 10 were combined
bone marrow and CNS relapse. The CNS relapses occurred at
a median of 231 days (range, 38 to 1414) after HSCT. Nine of
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Figure 1. Cumulative incidence of CNS relapse by pre-HSCT CNS involvement.
A. Hamdi et al. / Biol Blood Marrow Transplant 20 (2014) 1767e1771 1769these patients (50%) had pre-HSCT CNS involvement. Among
the 9 patients with CNS involvement before HSCT, 4 had CNS
involvement at diagnosis and 5 patients had CNS involve-
ment during ﬁrst relapse and underwent transplantation in
second CR.Figure 2. Cumulative incidence of (A) any relapse or (B) CNS relapse by CNS
prophylaxis using landmark analysis starting at day 100.
Table 3
Transplantation Outcomes, Univariate Analyses
Variable CNS relapse Total Relapse Overall Mortality
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Age, continuous variable .97 (.94-1.004) .08 .99 (.98-1.002) .09 1.01 (1.001-1.02) .03
Sex
Female - - - - - -
Male .69 (.27-1.73) .42 1.02 (.72-1.43) .92 1.12 (.86-1.44) .40
Lineage
B cell - - - - - -
T cell .83 (.19-3.59) .80 1.71 (1.10-2.67) .02 1.09 (.76-1.59) .61
Cytogenetic risk group * *
Good - - - -
Intermediate 1.21 (.55-2.67) .64 .83 (.45-1.53) .55
Poor 1.13 (.78-1.62) .52 .87 (.48-1.58) .65
Pre-CNS involvement 5.84 (2.33-14.64) .0002 1.17 (.73-1.86) .52 1.33 (.96-1.85) .09
Disease status
CR1 - - - - - -
CR2 1.47 (.59-3.69) .41 1.87 (1.34-2.63) .0003 1.95 (1.52-2.51) <.0001
Conditioning regimen
MA - - - - - -
Others .36 (.05-2.77) .33 1.20 (.75-1.91) .45 1.19 (.83-1.68) .34
Graft source * *
Bone marrow - - - -
Cord blood .66 (.31-1.39) .27 2.33 (1.52-3.57) .0001
Peripheral blood 1.25 (.84-1.87) .28 1.22 (.90-1.66) .20
Allotype
HLA-matched related - - - - - -
HLA-matched unrelated .50 (.17-1.43) .20 .70 (.48-1.03) .07 .88 (.66-1.18) .40
HLA-mismatched related .85 (.10-7.00) .89 .67 (.27-1.64) .38 1.40 (.78-2.50) .25
HLA-mismatched unrelated .20 (.03-1.54) .12 .57 (.34-.97) .04 1.53 (1.10-2.14) .01
Post-HSCT CNS prophylaxis 3.88 (.85-17.61) .08 1.22 (.82-1.83) .32 .47 (.36-.61) <.0001
Post-HSCT IT prophylactic cycles
<4 - - - - - -
4 2.54 (.77-8.41) .13 1.01 (.68-1.49) .98 .45 (.34-.60) <.0001
A. Hamdi et al. / Biol Blood Marrow Transplant 20 (2014) 1767e17711770Predictors of CNS Relapse
Patients with a previous history of CNS involvement with
leukemia had a signiﬁcantly higher rate for CNS relapse
compared with patients with no history of CSN involvement
before transplantation, 13.4% versus 2.6% (P ¼ .002); further-
more, patients who had CNS involvement in ﬁrst relapse,
compared with those with CNS involvement at diagnosis,
had the highest rate for CNS progression after transplantation
(Figure 1). We failed to ﬁnd a signiﬁcant effect of post-
transplantation intrathecal chemotherapy or radiation
therapy to prevent CNS relapse, or any relapse, after trans-
plantation (Figure 2A,B). The 4-year cumulative incidence of
CNS relapse was 6% and 1.5% for patients with and without
CNS prophylaxis after HSCT, respectively (P¼ .08) (Figure 2A).
No beneﬁt for post-transplantation CNS prophylaxis could be
detected when a subgroup analysis of patients with (P ¼ .10)
and without prior CNS involvement (P ¼ .52) was performed.
The 4-year rate of CNS relapse was also not affected by the
intensity of the transplantation conditioning regimen, P¼ .33,
as shown in univariate analysis in Table 3.
Predictors of Total Relapse and Overall Survival
The 4-year cumulative incidence of relapse after HSCT
among all patients was 32.3% and 27.9% for patients with and
without CNS prophylaxis after HSCT, respectively (P ¼ .32)
(Figure2B).Therewasnodifference insurvivalbetweenpatients
with andwithout pre-HSCT CNS disease (P¼ .09), although the
disease status (CR1 versus CR2 at time of transplantation)was a
signiﬁcant predictor of survival (P< .0001) (Table 3).
DISCUSSION
Effective strategies to control the primary disease and to
reduce the incidence of CNS relapse, including early andfrequentcombination therapywithsystemicCNSactiveagents,
CNS irradiation, and intrathecal therapy, have reduced the
incidence of CNS progression before and after transplantation
[13,14]. Indeed, the rate for CNS relapse after transplantation
wasonly4% inour studyand isconsistentwithpreviousstudies
that demonstrated that CNS relapse is an uncommon event
after HSCT for ALL in ﬁrst or second remission [4,7-10].
We failed to show a signiﬁcant beneﬁt for post-
transplantation CNS prophylaxis in preventing CNS relapse.
Previous studies have reported disparate effects for post-
HSCT CNS prophylaxis. Although some studies showed
beneﬁcial effects for post-HSCT CNS prophylaxis [10], others
have not shown beneﬁt [7,8], and still others showed even
adverse effects for prophylaxis as a result of clinical toxicity
[9]. In our study, one could note that the rate of CNS relapse
was higher in patients who received post-HSCT CNS pro-
phylaxis. This may be partially explained by the fact that the
rate of pre-HSCT CNS involvement was higher among pa-
tients who received CNS prophylaxis (19% versus 11%). In
addition, at MDACC, generally only patients with a predicted
higher rate for CNS relapse after transplantation (those with
previous CNS involvement) routinely received post-HSCT
prophylaxis (51% versus 13%, respectively, P < .001). Pa-
tients from FHCRC and RMC received post-HSCT CNS pro-
phylaxis routinely, but the numbers of patients were too
small to perform subgroup analyses by center.
A previous history of CNS involvement was the only
identiﬁed predictor for post-transplantation CNS relapse in
our study, similar to other reports [7,9,10]. In our study, the
incidence of CNS relapse after transplantation in patients
with pre-HSCT CNS involvement was 13%, which is consis-
tent with previously published rates of 0 to 27% [7-10].
Interestingly, our results showed that patients with CNS
A. Hamdi et al. / Biol Blood Marrow Transplant 20 (2014) 1767e1771 1771involvement at diagnosis had a lower rate of CNS relapse
compared with patients who developed CNS relapse in ﬁrst
relapse (Figure 1). This may, in part, be explained by differ-
ences in biology between the 2 groups and may also be
affected by differences in treatment approaches [15-18].
Importantly, the use of post-transplantation CNS prophylaxis
did not lower the rate.
Our study is limited by the retrospective nature of the
analyses and by the small number of post-transplantation
CNS relapses, which precluded extensive analyses of pre-
dictors for relapse and subpopulation analyses. Additionally,
complete toxicity data for patients who received CNS-
directed therapy were not available, as most patients had
left the transplantation center before completion of intra-
thecal therapy, and toxicity, if developed, was not reported to
the transplantation center. However, within this incomplete
reporting of CNS toxicity, 30 patients among the 217 who
received post-HSCT prophylaxis (14%) had reports of toxicity
ranging from postelumbar puncture headache (n ¼ 16) to
white matter changes noted on magnetic resonance imaging
and symptoms of encephalopathy (n ¼ 9). There was no
correlation with type of treatment or number of intrathecal
treatments. It is well established that intrathecal CNS therapy
can be associated with acute, subacute, and chronic neuro-
toxicities [19]. In addition, although CNS irradiation side ef-
fects are more pronounced in children, adults with older age
are susceptible to cerebral atrophy and neurocognitive deﬁ-
cits after CNS irradiation [20,21]. Thus, the potential for
toxicity needs to be taken into account when making the
decision to administer post-transplantation prophylaxis.
Identifying the patient population who may beneﬁt the
most from CNS prophylactic therapy may help increase the
clinical beneﬁt and avoid unnecessary treatment and toxicity.
Our results suggest that only patients with a previous history
of CNS involvementmay beneﬁt from post-HSCT prophylactic
CNS therapy, with a trend for less relapse. However, our
ﬁndings need to be conﬁrmed in a larger, prospective study.
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